Suppr
超能文献

Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.

作者信息

Giacobbe Daniele R, Bassetti Matteo

机构信息

Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS, Genoa, 16132, Italy.

Department of Health Sciences, University of Genoa, Genoa, 16132, Italy.

出版信息

Future Microbiol. 2022 Apr;17:393-396. doi: 10.2217/fmb-2021-0301. Epub 2022 Mar 2.

DOI:10.2217/fmb-2021-0301

PMID:35234517

Abstract

摘要

相似文献

Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.

Future Microbiol. 2022 Apr;17:393-396. doi: 10.2217/fmb-2021-0301. Epub 2022 Mar 2.

Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.

Int J Antimicrob Agents. 2024 May;63(5):107150. doi: 10.1016/j.ijantimicag.2024.107150. Epub 2024 Mar 19.

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?

Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):339-354. doi: 10.1007/s10096-023-04732-4. Epub 2023 Dec 14.

activity of cefiderocol against European and spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.

Microbiol Spectr. 2024 Apr 2;12(4):e0383623. doi: 10.1128/spectrum.03836-23. Epub 2024 Mar 14.

New β-Lactam-β-Lactamase Inhibitor Combinations.

Clin Microbiol Rev. 2020 Nov 11;34(1). doi: 10.1128/CMR.00115-20. Print 2020 Dec 16.

Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.

J Antimicrob Chemother. 2021 Jan 1;76(1):160-170. doi: 10.1093/jac/dkaa391.

In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.

Int J Antimicrob Agents. 2021 Nov;58(5):106440. doi: 10.1016/j.ijantimicag.2021.106440. Epub 2021 Sep 20.

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.

Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31.

In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.

J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. doi: 10.1093/jac/dkaa053.

Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant .

Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0112023. doi: 10.1128/aac.01120-23. Epub 2024 Jan 30.

引用本文的文献

A comprehensive investigation of the medicinal efficacy of antimicrobial fusion peptides expressed in probiotic bacteria for the treatment of pan drug-resistant (PDR) infections.

Arch Microbiol. 2024 Feb 8;206(3):93. doi: 10.1007/s00203-023-03823-2.

Treatment and diagnosis of severe KPC-producing infections: a perspective on what has changed over last decades.

Ann Med. 2023 Dec;55(1):101-113. doi: 10.1080/07853890.2022.2152484.

Current and Emerging Treatment Options for Multidrug Resistant Urosepsis: A Review.

Antibiotics (Basel). 2022 Dec 15;11(12):1821. doi: 10.3390/antibiotics11121821.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译